Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125076) titled 'The effects of biological agents targeting type 2 inflammation in stable phase bronchiectasis patients with type 2 inflammation' on May 21.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: West China Hospital of Sichuan University
Condition:
Bronchiectasis
Intervention:
Experimental group:biological agents targeting type 2 inflammation(including Dupilumab,Mepolizumab or Benralizumab)
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-05-27
Target Sample Size: Experimental group:49;Positive control group:49;
Countries of Recruitment:
China
To know ...